Gilead Will Eventually Come Storming Back

Although not a dividend aristocrat, Gilead (NASDAQ:GILD) is looking very attractive at these levels. Its earnings and sales multiples are much lower than the industry’s average. Furthemore it has a strong balance sheet with plenty of cash on hand to either innovate or acquire another drug/company. One bad year doesn’t make or break a company. It’s 10 year fundamentals are excellent and once the HCV complex settles down, I believe Gilead will rally strongly out of its current lows.


About Individual Trader

Helping You Navigate The Markets For Profit
This entry was posted in Gilead and tagged . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s